April 4, 2013

HELIX BIOPHARMA CORP. INITIATES ENROLLMENT FOR THIRD COHORT AND EXPANSION OF CENTRES

(Aurora, Ontario) – Helix BioPharma Corp. (TSX, FSE: “HBP”), a biopharmaceutical company developing innovative drug candidates for the prevention and treatment of cancer, today announced the opening of patient screening for the third dose level cohort in its ongoing Phase I/II clinical safety, tolerability and preliminary efficacy study of L-DOS47 in Poland. This follows completion of the first treatment cycle in the three patients enrolled in the second dose level cohort, in which L-DOS47 therapy was well tolerated as reviewed by the Trial Steering Committee. Patients to be enrolled in the third cohort will receive the next L-DOS47 dose level as planned in the study protocol, 0.33 micrograms of L-DOS47 per kilogram of patient body weight.